Skip to main content
Premium Trial:

Request an Annual Quote

Stratagene Licenses FullVelocity to Focus Diagnostics

NEW YORK, Dec. 5 (GenomeWeb News) - Stratagene signed a licensing agreement with Focus Diagnostics to market molecular diagnostics products based on its FullVelocity technology, the company said today.

 

Under the terms of the agreement, Focus Diagnostics will receive a non-exclusive license to Stratagene's FullVelocity technology, and Stratagene will help the company develop molecular diagnostic testing kits and products. Stratagene will manufacture any diagnostics products that arise from the collaboration, and Focus will commercialize these products globally.

 

Strategene will also manufacture and sell reagents to Focus that will be used in the company's national reference laboratory.

 

Financial details were not disclosed.

 

FullVelocity is a high-speed reagent system for quantitative PCR and QRT-PCR that enables users to make numerous copies of a target to detect the presence of specific DNA and RNA in medical specimens.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.